LEGN vs. EIDX, PRNB, AUTL, BLUE, ALNY, TEVA, GMAB, RPRX, BGNE, and BMRN
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Eidos Therapeutics (EIDX), Principia Biopharma (PRNB), Autolus Therapeutics (AUTL), bluebird bio (BLUE), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), and BioMarin Pharmaceutical (BMRN).
Legend Biotech (NASDAQ:LEGN) and Eidos Therapeutics (NASDAQ:EIDX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 31.4% of Eidos Therapeutics shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 70.1% of Eidos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Eidos Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -135.92%. Legend Biotech's return on equity of -27.91% beat Eidos Therapeutics' return on equity.
In the previous week, Legend Biotech had 17 more articles in the media than Eidos Therapeutics. MarketBeat recorded 17 mentions for Legend Biotech and 0 mentions for Eidos Therapeutics. Legend Biotech's average media sentiment score of 0.30 beat Eidos Therapeutics' score of 0.00 indicating that Legend Biotech is being referred to more favorably in the media.
Eidos Therapeutics received 85 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 64.89% of users gave Legend Biotech an outperform vote while only 63.20% of users gave Eidos Therapeutics an outperform vote.
Legend Biotech has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Eidos Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500.
Legend Biotech currently has a consensus target price of $81.10, indicating a potential upside of 97.71%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Eidos Therapeutics.
Eidos Therapeutics has lower revenue, but higher earnings than Legend Biotech. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Legend Biotech beats Eidos Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Legend Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Legend Biotech Competitors List
Related Companies and Tools
